drugset / Trial / NCT00471718
ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Phase 1/2
Terminated
27 enrolled
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I/II trial is studying the side effects and best dose of ABT-751 and to see how well it works in treating patients with metastatic prostate cancer that did not respond to hormone therapy.
Timeline
- Start
- 2004-01
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABT-751 | Other / unclassified | 100 mg | Oral |
| Subject | ABT-751 | Other / unclassified | 125 mg | Oral |
| Subject | ABT-751 | Other / unclassified | 150 mg | Oral |
| Subject | ABT-751 | Other / unclassified | 175 mg | Oral |
| Subject | ABT-751 | Other / unclassified | 200 mg | Oral |